|
2026-09-15 |
2026-09-14 |
V
Vente
|
Chief Transformation Officer
Dirigeant
|
72 868
-24.6%
456,17
1 726 405 $US
|
72 868
-24.6%
|
456,17
|
1 726 405 $US
|
|
|
2026-09-10 |
2026-09-10 |
PrS
Vente proposée
|
Chief Transformation Officer
Dirigeant
|
91 377
250,66
4 551 337 $US
|
91 377
|
250,66
|
4 551 337 $US
|
|
|
2026-09-03 |
2026-09-02 |
PlS
Vente planifiée
|
President, R&D
Administrateur exécutif
|
68 583
+3.6%
250,92
3 511 874 $US
|
68 583
+3.6%
|
250,92
|
3 511 874 $US
|
|
|
2026-09-02 |
2026-09-02 |
PrS
Vente proposée
|
Officer
Dirigeant
|
1 000
18,49
100 000 $US
|
1 000
|
18,49
|
100 000 $US
|
|
|
2026-08-21 |
2026-08-19 |
PlS
Vente planifiée
|
President, R&D
Administrateur exécutif
|
19 651
-7.0%
18,49
363 347 $US
|
19 651
-7.0%
|
18,49
|
363 347 $US
|
|
|
2026-08-19 |
2026-08-19 |
PrS
Vente proposée
|
Officer
Dirigeant
|
19 651
18,49
363 348 $US
|
19 651
|
18,49
|
363 348 $US
|
|
|
2026-08-19 |
2026-08-18 |
V
Vente
|
Chief Human Resources Officer
Dirigeant
|
12 980
-24.5%
18,11
235 118 $US
|
12 980
-24.5%
|
18,11
|
235 118 $US
|
|
|
2026-08-14 |
2026-08-14 |
PrS
Vente proposée
|
Chief Human Resources Officer
Dirigeant
|
12 980
17,39
225 722 $US
|
12 980
|
17,39
|
225 722 $US
|
|
|
2026-08-12 |
2026-08-11 |
V
Vente
|
Pres., Global Supply & Quality
Dirigeant
|
20 363
-23.2%
17,55
357 371 $US
|
20 363
-23.2%
|
17,55
|
357 371 $US
|
|
|
2026-08-10 |
2026-08-11 |
PrS
Vente proposée
|
President, Global Supply & Quality
|
20 363
17,45
355 334 $US
|
20 363
|
17,45
|
355 334 $US
|
|
|
2026-08-12 |
2026-08-10 |
V
Vente
|
President, PDT BU
Dirigeant
|
7 277
-6.6%
17,10
124 437 $US
|
7 277
-6.6%
|
17,10
|
124 437 $US
|
|
|
2026-08-12 |
2026-08-10 |
V
Vente
|
Chief Medical Officer
Dirigeant
|
14 006
-10.8%
17,10
239 503 $US
|
14 006
-10.8%
|
17,10
|
239 503 $US
|
|
|
2026-08-12 |
2026-08-10 |
V
Vente
|
Chief Transformation Officer
Dirigeant
|
47 586
-17.4%
17,10
813 721 $US
|
47 586
-17.4%
|
17,10
|
813 721 $US
|
|
|
2026-08-12 |
2026-08-10 |
V
Vente
|
President, U.S. Business Unit
Dirigeant
|
16 901
-8.5%
17,10
289 007 $US
|
16 901
-8.5%
|
17,10
|
289 007 $US
|
|
|
2026-08-12 |
2026-08-10 |
V
Vente
|
President, R&D
Administrateur exécutif
|
165 393
-17.7%
17,10
2 828 220 $US
|
165 393
-17.7%
|
17,10
|
2 828 220 $US
|
|
|
2026-08-12 |
2026-08-10 |
V
Vente
|
Head, Strat. & Port. Dev
Dirigeant
|
22 957
-11.5%
17,10
392 565 $US
|
22 957
-11.5%
|
17,10
|
392 565 $US
|
|
|
2026-08-12 |
2026-08-10 |
V
Vente
|
President, OBU
Dirigeant
|
50 012
-16.6%
17,10
855 205 $US
|
50 012
-16.6%
|
17,10
|
855 205 $US
|
|
|
2026-08-12 |
2026-08-10 |
V
Vente
|
Pres., Global Supply & Quality
Dirigeant
|
3 978
-5.9%
17,10
68 024 $US
|
3 978
-5.9%
|
17,10
|
68 024 $US
|
|
|
2026-08-12 |
2026-08-10 |
V
Vente
|
Chief Data & Tech. Officer
Dirigeant
|
25 088
-12.8%
17,10
429 005 $US
|
25 088
-12.8%
|
17,10
|
429 005 $US
|
|
|
2026-08-12 |
2026-08-10 |
V
Vente
|
Chief Human Resources Officer
Dirigeant
|
6 774
-11.3%
17,10
115 835 $US
|
6 774
-11.3%
|
17,10
|
115 835 $US
|
|
|
2026-08-12 |
2026-08-10 |
V
Vente
|
President, IBU
Dirigeant
|
31 083
-9.0%
17,10
531 519 $US
|
31 083
-9.0%
|
17,10
|
531 519 $US
|
|
|
2026-08-12 |
2026-08-10 |
V
Vente
|
President and CEO
Administrateur exécutif
|
89 090
-18.5%
17,10
1 523 439 $US
|
89 090
-18.5%
|
17,10
|
1 523 439 $US
|
|
|
2026-08-12 |
2026-08-10 |
V
Vente
|
Global General Counsel
Dirigeant
|
30 868
-13.1%
17,10
527 843 $US
|
30 868
-13.1%
|
17,10
|
527 843 $US
|
|
|
2026-08-12 |
2026-08-10 |
V
Vente
|
Chief Human Resources Officer
Dirigeant
|
33 628
-36.0%
17,51
588 715 $US
|
33 628
-36.0%
|
17,51
|
588 715 $US
|
|
|
2026-08-12 |
2026-08-10 |
V
Vente
|
Chief Human Resources Officer
Dirigeant
|
975
-1.0%
17,50
17 062 $US
|
975
-1.0%
|
17,50
|
17 062 $US
|
|
|
2026-08-06 |
2026-08-07 |
PrS
Vente proposée
|
Chief Human Resources Officer
Dirigeant
|
34 603
16,72
578 562 $US
|
34 603
|
16,72
|
578 562 $US
|
|
|
2026-07-13 |
2026-07-13 |
PrS
Vente proposée
|
President, Global Oncology Business Unit
|
54 210
16,75
908 019 $US
|
54 210
|
16,75
|
908 019 $US
|
|
|
2026-07-13 |
2026-07-13 |
PrS
Vente proposée
|
Interim Head, Strategy and Portfolio Development
|
24 887
16,75
416 850 $US
|
24 887
|
16,75
|
416 850 $US
|
|
|
2026-07-13 |
2026-07-13 |
PrS
Vente proposée
|
Chief Human Resources Officer
Dirigeant
|
7 348
16,75
123 072 $US
|
7 348
|
16,75
|
123 072 $US
|
|
|
2026-07-13 |
2026-07-13 |
PrS
Vente proposée
|
President, Research & Development
|
179 239
16,75
3 002 258 $US
|
179 239
|
16,75
|
3 002 258 $US
|
|
|
2026-07-13 |
2026-07-13 |
PrS
Vente proposée
|
Chief Data & Technology Officer
Dirigeant
|
27 197
16,75
455 545 $US
|
27 197
|
16,75
|
455 545 $US
|
|
|
2026-07-13 |
2026-07-13 |
PrS
Vente proposée
|
President and CEO
|
96 558
16,75
1 617 344 $US
|
96 558
|
16,75
|
1 617 344 $US
|
|
|
2026-07-13 |
2026-07-13 |
PrS
Vente proposée
|
President, International Business Unit
|
33 696
16,75
564 406 $US
|
33 696
|
16,75
|
564 406 $US
|
|
|
2026-07-13 |
2026-07-13 |
PrS
Vente proposée
|
President, Global Supply & Quality
|
4 319
16,75
72 351 $US
|
4 319
|
16,75
|
72 351 $US
|
|
|
2026-07-13 |
2026-07-13 |
PrS
Vente proposée
|
Global General Counsel
|
33 454
16,75
560 351 $US
|
33 454
|
16,75
|
560 351 $US
|
|
|
2026-07-13 |
2026-07-13 |
PrS
Vente proposée
|
Chief Transformation Officer
Dirigeant
|
51 579
16,75
863 947 $US
|
51 579
|
16,75
|
863 947 $US
|
|
|
2026-07-13 |
2026-07-13 |
PrS
Vente proposée
|
Chief Medical Officer
Dirigeant
|
15 188
16,75
254 399 $US
|
15 188
|
16,75
|
254 399 $US
|
|
|
2026-07-13 |
2026-07-13 |
PrS
Vente proposée
|
President, US Business Unit and US Country Head
|
18 316
16,75
306 789 $US
|
18 316
|
16,75
|
306 789 $US
|
|
|
2026-07-13 |
2026-07-13 |
PrS
Vente proposée
|
President, Plasma-Derived Therapies Business Unit
|
7 889
16,75
132 149 $US
|
7 889
|
16,75
|
132 149 $US
|
|
|
2025-12-09 |
2025-12-09 |
PrS
Vente proposée
|
Chief Human Resources Officer
Dirigeant
|
29 619
14,22
421 182 $US
|
29 619
|
14,22
|
421 182 $US
|
|
|
2025-12-05 |
2025-12-05 |
PrS
Vente proposée
|
President, Global Oncology Business Unit
|
87 023
14,28
1 242 688 $US
|
87 023
|
14,28
|
1 242 688 $US
|
|
|
2025-12-04 |
2025-12-04 |
PrS
Vente proposée
|
President, Plasma-Derived Therapies Business Unit
|
58 421
14,31
836 005 $US
|
58 421
|
14,31
|
836 005 $US
|
|
|
2025-07-09 |
2025-07-09 |
PrS
Vente proposée
|
Chief Executive Officer
Dirigeant
|
34 857
15,42
537 495 $US
|
34 857
|
15,42
|
537 495 $US
|
|
|
2025-07-09 |
2025-07-09 |
PrS
Vente proposée
|
Corporate Strategy Officer & CEO Chief of Staff
Dirigeant
|
5 608
15,42
86 475 $US
|
5 608
|
15,42
|
86 475 $US
|
|
|
2025-07-09 |
2025-07-09 |
PrS
Vente proposée
|
Global Quality Officer
Dirigeant
|
4 477
15,42
69 035 $US
|
4 477
|
15,42
|
69 035 $US
|
|
|
2025-07-09 |
2025-07-09 |
PrS
Vente proposée
|
Global Business Development Officer
Dirigeant
|
18 622
15,42
287 151 $US
|
18 622
|
15,42
|
287 151 $US
|
|
|
2025-07-09 |
2025-07-09 |
PrS
Vente proposée
|
Chief Data & Technology Officer
Dirigeant
|
26 874
15,42
414 397 $US
|
26 874
|
15,42
|
414 397 $US
|
|
|
2025-07-09 |
2025-07-09 |
PrS
Vente proposée
|
Chief Human Resources Officer
Dirigeant
|
40 919
15,42
630 971 $US
|
40 919
|
15,42
|
630 971 $US
|
|
|
2025-07-09 |
2025-07-09 |
PrS
Vente proposée
|
Global Manufacturing & Supply Officer
Dirigeant
|
6 136
15,42
94 617 $US
|
6 136
|
15,42
|
94 617 $US
|
|
|
2025-07-09 |
2025-07-09 |
PrS
Vente proposée
|
President, US Business Unit
|
58 559
15,42
902 980 $US
|
58 559
|
15,42
|
902 980 $US
|
|
|
2025-07-09 |
2025-07-09 |
PrS
Vente proposée
|
President, Research & Development
|
169 313
15,42
2 610 806 $US
|
169 313
|
15,42
|
2 610 806 $US
|
|
|
2025-07-09 |
2025-07-09 |
PrS
Vente proposée
|
President, Plasma-Derived Therapies Business Unit
|
28 552
15,42
440 272 $US
|
28 552
|
15,42
|
440 272 $US
|
|
|
2025-07-09 |
2025-07-09 |
PrS
Vente proposée
|
President, Global Oncology Business Unit
|
52 649
15,42
811 848 $US
|
52 649
|
15,42
|
811 848 $US
|
|
|
2025-07-09 |
2025-07-09 |
PrS
Vente proposée
|
President, Global Portfolio Division
|
102 972
15,42
1 587 828 $US
|
102 972
|
15,42
|
1 587 828 $US
|
|
|
2024-08-22 |
2024-08-23 |
PrS
Vente proposée
|
President, Plasma-Derived Therapies Business Unit
|
19 073
14,94
284 951 $US
|
19 073
|
14,94
|
284 951 $US
|
|
|
2024-07-10 |
2024-07-11 |
PrS
Vente proposée
|
Global Manufacturing & Supply Officer
Dirigeant
|
4 533
13,18
59 745 $US
|
4 533
|
13,18
|
59 745 $US
|
|
|
2024-07-10 |
2024-07-11 |
PrS
Vente proposée
|
President, Global Oncology Business Unit
|
38 479
13,18
507 153 $US
|
38 479
|
13,18
|
507 153 $US
|
|
|
2024-07-10 |
2024-07-11 |
PrS
Vente proposée
|
President, Global Portfolio Division
|
74 654
13,18
983 940 $US
|
74 654
|
13,18
|
983 940 $US
|
|
|
2024-07-10 |
2024-07-11 |
PrS
Vente proposée
|
Global Business Development Officer
Dirigeant
|
10 674
13,18
140 683 $US
|
10 674
|
13,18
|
140 683 $US
|
|
|
2024-07-10 |
2024-07-11 |
PrS
Vente proposée
|
Chief Human Resources Officer
Dirigeant
|
27 603
13,18
363 808 $US
|
27 603
|
13,18
|
363 808 $US
|
|
|
2024-07-10 |
2024-07-11 |
PrS
Vente proposée
|
President, US Business Unit
|
37 219
13,18
490 546 $US
|
37 219
|
13,18
|
490 546 $US
|
|
|
2024-07-10 |
2024-07-11 |
PrS
Vente proposée
|
President, Plasma-Derived Therapies Business Unit
|
20 721
13,18
273 103 $US
|
20 721
|
13,18
|
273 103 $US
|
|
|
2024-07-10 |
2024-07-11 |
PrS
Vente proposée
|
Chief Data & Technology Officer
Dirigeant
|
6 132
13,18
80 820 $US
|
6 132
|
13,18
|
80 820 $US
|
|
|
2024-07-10 |
2024-07-11 |
PrS
Vente proposée
|
Global Quality Officer
Dirigeant
|
4 612
13,18
60 786 $US
|
4 612
|
13,18
|
60 786 $US
|
|
|
2024-07-10 |
2024-07-11 |
PrS
Vente proposée
|
Chief Executive Officer
Dirigeant
|
14 890
13,18
196 250 $US
|
14 890
|
13,18
|
196 250 $US
|
|
|
2024-07-10 |
2024-07-11 |
PrS
Vente proposée
|
President, Research & Development
|
121 125
13,18
1 596 428 $US
|
121 125
|
13,18
|
1 596 428 $US
|
|
|
2024-07-10 |
2024-07-11 |
PrS
Vente proposée
|
Corporate Strategy Officer & CEO Chief of Staff
Dirigeant
|
6 048
13,18
79 713 $US
|
6 048
|
13,18
|
79 713 $US
|
|
|
2023-07-10 |
2023-07-11 |
PrS
Vente proposée
|
Global Manufacturing & Supply Officer
Dirigeant
|
4 789
15,48
74 134 $US
|
4 789
|
15,48
|
74 134 $US
|
|
|
2023-07-10 |
2023-07-11 |
PrS
Vente proposée
|
President, Global Oncology Business Unit
|
46 424
15,48
718 645 $US
|
46 424
|
15,48
|
718 645 $US
|
|
|
2023-07-10 |
2023-07-11 |
PrS
Vente proposée
|
President, Global Portfolio Division
|
68 184
15,48
1 055 490 $US
|
68 184
|
15,48
|
1 055 490 $US
|
|
|
2023-07-10 |
2023-07-11 |
PrS
Vente proposée
|
Chief Ethics & Compliance Officer
Dirigeant
|
2 045
15,48
31 654 $US
|
2 045
|
15,48
|
31 654 $US
|
|
|
2023-07-10 |
2023-07-11 |
PrS
Vente proposée
|
Global Business Development Officer
Dirigeant
|
10 522
15,48
162 874 $US
|
10 522
|
15,48
|
162 874 $US
|
|
|
2023-07-10 |
2023-07-11 |
PrS
Vente proposée
|
Chief Human Resources Officer
Dirigeant
|
10 732
15,48
166 131 $US
|
10 732
|
15,48
|
166 131 $US
|
|
|
2023-07-10 |
2023-07-11 |
PrS
Vente proposée
|
President, US Business Unit
|
29 403
15,48
455 154 $US
|
29 403
|
15,48
|
455 154 $US
|
|
|
2023-07-10 |
2023-07-11 |
PrS
Vente proposée
|
President, Plasma-Derived Therapies Business Unit
|
24 394
15,48
377 620 $US
|
24 394
|
15,48
|
377 620 $US
|
|